Glycogen as a Putative Target for Diagnosis and Therapy in Brain Pathologies

Table 2

Summarized latency (min) obtained during characterization of MSO-Fast and MSO-Slow lines at the 6th generation of selection process.

Products	Mouse
	MSO-Fast	𝑛	MSO-Slow	𝑛
Convulsant
MSO (75 mg/kg)	295,6±102,4^a	20	ND
MSO (200 mg/kg)	ND		347,7±79,5	20
KA (25 mg/kg)	48,8±23,2^a	28	76,8±46,5	27
PTZ (75 mg/kg)	1,24±0,48^b	30	1,18±0,46	29
Anticonvulsant
MK-801 (1 mg/kg)	600^c	12	600^c	12
VPA (250 mg/kg)	453,7±65,1^d	10	470,5±183,6	10

The anticonvulsants were given to mice 30 minutes before the appropriate dose of MSO. ^a: P < 0.01 MSO-Fast versus MSO-Slow. ^b: NS. ^c: The anticonvulsant effect of MK-801 is obvious, but not statistically analyzed as the latency value in its presence has no SEM. Indeed, when the latency is above 10 hours, mice were given a score of 600. ^d: P < 0.001 VPA versus its absence in MSO-Fast only. ND: not determined. Data adapted from Cloix et al. [113].